黄芪首乌化纤汤与金水宝胶囊抗乙型肝炎肝纤维化疗效比较

Comparison on Efficacy in Treating Liver Fibrosis of Chronic Hepatitis B between Astragalus Polygonum AntiFibrosis Decoction and Jinshuibao Capsule

观察中药复方黄芪首乌化纤汤抗慢性乙型肝炎（慢性乙肝）肝纤维化的作用，寻找抗肝纤维化有效中药复方。方法：慢性乙肝肝纤维化患者９２例，随机分为黄芪首乌化纤汤治疗组４７例，虫草孢子菌丝制剂金水宝胶囊对照组４５例，进行为期４８周的对照治疗。对照治疗前后肝纤维化４项血清学指标：透明质酸（ＨＡ）、层粘连蛋白（ＬＮ）、Ⅲ型前胶原（ＰＣⅢ）、Ⅳ型胶原（ＣⅣ）；肝功能主要指标：总胆红素（ＴＢ）、丙氨酸转氨酶（ＡＬＴ）、白／球蛋白（Ａ／Ｇ）比例；肝炎相关血清生化指标：甘胆酸（ＣＧ）、铁蛋白（ＳＦ）、前白蛋白（ＰＡ）。结果：治疗组ＨＡ、ＬＮ、ＰＣⅢ及ＣⅣ均有明显下降，两组比较有显著性差异（Ｐ＜０．０１）；两组治疗前后ＴＢ、ＡＬＴ和肝炎相关血清生化指标ＣＧ、ＳＦ值治疗组较对照组明显下降，而Ａ／Ｇ、ＰＡ则明显升高，两组比较有显著性差异（Ｐ＜０．０１）。结论：黄芪首乌化纤汤抗慢性乙肝肝纤维化比金水宝胶囊更加有效，对肝脏炎症的抑制更明显，是一种抗肝纤维化的良好复方中药制剂。

To observe the efficacy of Astragalus-Polygonum Anti-Fibrosis Decoction (APAFD) and Jin shuibao capsule (JSBC) in treating liver fibrosis of chronic hepatitis B. Methods: Ninety-two liver fibrosis of chronic hepatitis B patients were randomly divided into group A and B. Patients in group A received APAFD for 48 weeks, and in group B, they received JSBC for 48 weeks. The effects were observed on the change of hyaluronic acid (HA), laminin (LN), pro-collagen Ⅲ (PCⅢ) and collagen Ⅳ (CⅣ) as well as liver functional tests and liver biochemical parameters before and after treatment. Results: Levels of serum HA, LN, PCⅢ and CⅣ in the group A declined more obviously than that of group B, the difference was significant (P<0.01). The liver functional tests such as total bilirubin (TB), alanine aminotransferase (ALT), albumin/globulin ratio, hepatitis related serum biochemical parameters such as cholylglycine (CG), serum ferritin (SF), prealbumin (PA) of group A all were improved more significantly than that of group B (P<0. 01). Conclusion: APAFD is more effective than JSBC in treating liver fibrosis of chronic hepatitis B, and in the inhibition of hepatic inflammation, it is a good composite Chinese herbal preparation against liver fibrosis.